Subdural Hematoma (Chronic)

1. Comprehensive Introduction & Overview

A Chronic Subdural Hematoma (CSDH) is a clinical entity defined as a collection of venous blood and its breakdown products located between the dural border layer (the inner surface of the dura mater) and the arachnoid mater. Unlike an acute subdural hematoma, which presents as a life-threatening medical emergency following high-energy trauma, a chronic subdural hematoma is characterized by its insidious progression.

Clinically, a hematoma is classified as "chronic" if it has been present for at least two to three weeks post-insult. It is predominantly a disease of the elderly, with a rising incidence due to an aging global population, the widespread use of anticoagulant and antiplatelet therapies, and the prevalence of cerebral atrophy. The classic presentation—a minor head trauma followed by a slow, progressive decline in cognitive or neurological function—often mimics dementia, stroke, or depression, leading to significant diagnostic challenges in clinical practice.

2. Deep-Dive: Etiology and Pathophysiology

The Mechanism of Formation

The pathophysiology of CSDH is a complex, multi-stage process that transcends simple mechanical trauma. While trauma is the most common precipitating event, the "chronic" nature of the lesion is driven by a self-perpetuating cycle of inflammation and neoangiogenesis.

1. Initial Insult: A minor shearing force tears the "bridging veins" that traverse the subdural space. In elderly patients, cerebral atrophy increases the distance between the cortex and the dura, effectively lengthening these veins and increasing their vulnerability to minor movement.
2. The Inflammatory Cascade: The presence of blood in the subdural space triggers an inflammatory response. The breakdown of blood products (erythrocytes) releases proinflammatory cytokines, including Interleukin-6 (IL-6) and Vascular Endothelial Growth Factor (VEGF).
3. Neoangiogenesis: The hematoma membrane becomes highly vascularized. These new, fragile capillaries (neomembranes) lack a mature basement membrane, making them prone to recurrent micro-hemorrhages.
4. Osmotic Expansion: The degradation of proteins within the hematoma increases the osmotic pressure, drawing fluid into the collection and further expanding the hematoma volume.

Risk Factors

3. Clinical Staging and Grading

To standardize treatment and prognosis, clinicians often utilize the Markwalder Grading Scale (MGS):

4. Clinical Presentation and Differential Diagnosis

Standard Presentation

The clinical picture is often protean. Patients rarely present with the classic "lucid interval" seen in epidural hematomas. Instead, symptoms develop over weeks or months:
* Cognitive Decline: Memory loss, executive dysfunction, and slowed processing speed.
* Motor Deficits: Unilateral weakness or gait disturbance (often mistaken for Parkinsonism).
* Headache: Usually dull, persistent, and non-localizing.
* Seizures: Focal or generalized, resulting from cortical irritation.

Differential Diagnosis

Because CSDH is a "great masquerader," the differential must be exhaustive:
* Dementia/Neurodegenerative Disease: Particularly in elderly patients with chronic cognitive decline.
* Subacute Ischemic Stroke: Especially if the patient has vascular risk factors.
* Brain Tumor: Specifically subdural empyema or metastatic lesions.
* Normal Pressure Hydrocephalus (NPH): Characterized by the triad of gait disturbance, urinary incontinence, and dementia.

5. Key Diagnostic Tests

Imaging Modalities

• Computed Tomography (CT) without Contrast: The gold standard. A CSDH appears as a hypodense (darker than brain tissue) or isodense (same density as brain) crescent-shaped collection. If the hematoma is mixed-density, it suggests recurrent bleeding.
• Magnetic Resonance Imaging (MRI): More sensitive than CT for isodense hematomas. MRI provides superior detail on the hematoma membranes and the presence of underlying brain edema.

Laboratory Investigations

• Coagulation Profile: PT/INR and PTT are mandatory to rule out underlying coagulopathy.
• Complete Blood Count (CBC): To assess for anemia or systemic infection.

6. Management and Therapeutic Approaches

Conservative Management

Indicated for small, asymptomatic hematomas (Markwalder Grade 0-1). This includes serial imaging, cessation of anticoagulants, and strict monitoring for neurological deterioration.

Surgical Intervention

The definitive treatment for symptomatic CSDH.
* Burr Hole Craniostomy: The most common approach. A small hole is drilled, the hematoma is evacuated, and a closed-system drain is left in place for 24–48 hours to prevent re-accumulation.
* Craniotomy: Reserved for solid, organized hematomas or when the membrane is too thick to drain through a burr hole.
* Middle Meningeal Artery (MMA) Embolization: An emerging, minimally invasive technique. By embolizing the MMA, surgeons can deprive the hematoma of its blood supply, preventing recurrence.

7. Risks, Complications, and Prognosis

Complications

• Recurrence: Occurs in 10-20% of patients.
• Seizures: Post-operative seizures occur in a subset of patients, requiring prophylaxis in some centers.
• Infection: Subdural empyema or meningitis following surgical drainage.
• Pneumocephalus: Air entering the intracranial space post-surgery.

Long-term Prognosis

The prognosis for CSDH is generally favorable if treated promptly. Most patients experience significant neurological recovery. However, mortality rates remain higher in the elderly population, often related to systemic complications (e.g., pneumonia, cardiac events) rather than the hematoma itself.

8. FAQ: Frequently Asked Questions

1. Can a chronic subdural hematoma resolve on its own?
Yes, small, asymptomatic hematomas can occasionally resolve spontaneously through natural resorption, though this requires close observation with serial CT scans.

2. Why is CSDH more common in the elderly?
Cerebral atrophy in the elderly causes the brain to shrink away from the skull, stretching the bridging veins and creating more space for blood to collect.

3. What is the role of steroids in treating CSDH?
While historically used to reduce inflammation, the use of corticosteroids remains controversial due to systemic side effects like hyperglycemia and increased risk of infection, especially in the elderly.

4. How long does the recovery take after surgery?
Most patients show immediate improvement, with full recovery typically achieved within 4 to 8 weeks, depending on the severity of preoperative deficits.

5. Is surgery always required?
No. If the patient is asymptomatic and the hematoma is small, a "watch and wait" approach is standard.

6. Does the hematoma come back after surgery?
Yes, recurrence occurs in roughly 10% to 20% of cases. Risk factors for recurrence include large hematoma size, bilateral presence, and continued use of anticoagulants.

7. Can I resume blood thinners after surgery?
This is a critical clinical decision. Generally, surgeons wait 1–2 weeks post-surgery before cautiously reintroducing anticoagulants, balancing the risk of stroke against the risk of hematoma recurrence.

8. What symptoms should a patient watch for after discharge?
Patients must seek immediate medical attention if they experience worsening headaches, confusion, weakness, speech difficulty, or seizures.

9. Is a CSDH a form of stroke?
No, it is not a stroke. A stroke involves a vascular event within the brain tissue itself, whereas a CSDH is a collection of blood outside the brain tissue.

10. How does MMA Embolization work?
The Middle Meningeal Artery provides blood to the hematoma's neomembranes. By blocking this artery, the blood supply to the membranes is cut off, causing the hematoma to shrink and preventing further growth.

9. Conclusion

Chronic Subdural Hematoma remains a significant clinical challenge requiring a high index of suspicion, particularly in aging populations. While surgical evacuation remains the cornerstone of therapy, the field is shifting toward less invasive modalities like MMA embolization. Early detection and management of underlying coagulopathies are essential to improving outcomes and minimizing the risk of recurrence. As our understanding of the inflammatory nature of CSDH evolves, so too will our ability to manage this condition with precision and efficacy.